Funding Briefs

More Millions For Fellowships? Changes may be afoot in the handling of the Markey Trust. Ever since 1983, a year after Lucille P. Markey, owner of thorough-bred breeding stable Calumet Farms, died in Miami, the Lucille P. Markey Charitable Trust has been spending about $40 million a year on biomedical research. Markey’s goal was for her foundation to spend both the endowment ($300 million) and its income within 15 years, and quietly go out of business. So far, the foundation has funded b

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Changes may be afoot in the handling of the Markey Trust. Ever since 1983, a year after Lucille P. Markey, owner of thorough-bred breeding stable Calumet Farms, died in Miami, the Lucille P. Markey Charitable Trust has been spending about $40 million a year on biomedical research. Markey’s goal was for her foundation to spend both the endowment ($300 million) and its income within 15 years, and quietly go out of business. So far, the foundation has funded biomedical research projects to the tune of approximately $240 million. But as the trustees hit the half-mile pole on the way to their 1997 deadline for spending themselves out of business, they have begun to debate their tactics in the spending race to the wire. In February, the trustees held a brainstorming session to review priorities for the remaining years. Some reportedly argued for dramatically increasing the amounts allocated to the competitive ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies